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We examine the role of diﬀerent network capabilities of companies that inﬂuence the
formation of R&D partnerships in pharmaceutical biotechnology. Strategic network
capabilities, speciﬁcally centrality-based capabilities and the eﬃciency with which
companies choose their partners, are found to facilitate the formation of new
partnerships. Unlike general experience with partnering, these strategic network
capabilities play a crucial role in enabling companies to continue to interact with other
companies through partnerships in a complex network setting.
Introduction
Experience with the formation of inter-ﬁrm
partnerships and the further development of
related partnering capabilities by companies play
an important role in the current discussion on
inter-ﬁrm partnership formation (see e.g. Anand
and Khanna, 2000; Gulati, 1995; Kale and Singh,
1999; Rothaermel and Deeds, 2001; Saxton,
1997). Previous research indicates that partnering
capabilities of companies can inﬂuence the like-
lihood that companies will continue to form
inter-ﬁrm partnerships. In order to contribute to
this body of literature, our study will attempt to
deepen the understanding of partnering capabil-
ities by considering speciﬁc network capabilities
of companies. This article stresses the importance
of comprehending the role of network capabil-
ities, in particular capabilities related to strategic
network positioning of companies and capabil-
ities regarding the eﬃciency with which they
choose their partners. Our perception of these
two speciﬁc strategic network capabilities is
based on crucial concepts from the social net-
work literature that, in our opinion, can play a
substantial role in the further development of the
theoretical and empirical analysis of inter-ﬁrm
partnerships. From a more practical and manage-
rial perspective, the main questions of our
contribution relate to the degree to which the
strategic positioning of companies in inter-ﬁrm
networks enables them to successfully keep
searching for future partners. In that context,
companies can consider strategic options in
which they are either very selective and eﬃcient
in their partner choice or rather indiscriminate as
they follow a strategy in which they simply ‘shop
around’ and use every opportunity there is for
forming partnerships. We also reﬂect on the
question of whether companies that strategically
position themselves in between a lot of other
companies beneﬁt from such a central position as
they are being invited to participate in future
partnering activities.
1The authors would like to thank three anonymous
referees and John Bessant for their suggestions and
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is found in a high-tech industry, the pharmaceu-
tical biotechnology sector, where there is an
abundance of inter-ﬁrm partnerships (Roijakkers
and Hagedoorn, 2003; Rothaermel and Deeds,
2001; Shan, Walker and Kogut, 1994).
In the next section, we will ﬁrst discuss the role
of experience and learning in relation to general
partnering capabilities of companies. This brief
outline of the role of experience, learning and
partnering capabilities provides us with a back-
ground for a further discussion of our hypoth-
eses. These hypotheses stipulate the expected
eﬀects of diﬀerent aspects of particular strategic
network capabilities on future inter-ﬁrm partner-
ing. In order to test the hypotheses, we con-
structed a relatively large panel data set that
contains information about partnerships and
relevant characteristics of companies in the
population over time. In a methodological
section we brieﬂy describe the research setting
of the pharmaceutical biotechnology industry
and the population, we discuss the variables used
in this study, we present our data sources and we
outline the use of a group-based ﬁxed eﬀects logit
approach to the analysis of panel data. A more
technical outline of some network measures is
given in Appendix I. The methodological section
is followed by a presentation and discussion of
the results of our study, with speciﬁc attention to
managerial implications of our ﬁndings. Lastly,
we present some of the major conclusions to be
drawn from this research.
Theory development and hypotheses
Following the literature on learning and cap-
ability development, we understand the experi-
ence that a company has with performing its
main economic functions to create certain en-
dogenous capabilities. If the company is success-
ful in creating endogenous capabilities, it can
gradually develop these capabilities even further
in order to perform its economic functions more
eﬃciently than many of its competitors (see also
Nelson and Winter, 1982; Teece, Pisano and
Shuen, 1997). This experience of a company with
developing its capabilities generates a stock of
accumulated knowledge of both an explicit and a
tacit nature, which is somewhat diﬃcult to access
for other companies (Kogut and Zander, 1992).
This accumulated knowledge base of a company
also creates an absorptive capacity that enables it
to learn from a variety of both internal and
external sources (Cohen and Levinthal, 1990;
Lane and Lubatkin, 1996; Mowery, Oxley and
Silverman, 1998; Stock, Greis and Fischer, 2001;
Tsai, 2001).
Inter-ﬁrm partnerships, the sharing of re-
sources by separate companies, are clear exam-
ples of the exterior sources that can be used to
externally acquire know-how to complement a
ﬁrm’s existing knowledge. However, it is well
known from the literature that inter-ﬁrm partner-
ships are diﬃcult to manage because of their
rather complicated nature and because it is
practically impossible to specify the concrete
results of many joint eﬀorts in advance (Anand
and Khanna, 2000; Chung, Singh and Lee, 2000).
Furthermore, inter-ﬁrm partnerships are by
deﬁnition linked to more than one company
where shared responsibilities increase potential
managerial complexity. Therefore, considerable
scope for useful learning by a company exists in
the opportunity to improve its ability to antici-
pate and eﬀectively respond to contingencies that
may unfold as it interacts with various partners.
This learning experience through partnerships
can be developed further through frequent
interactions with a variety of diﬀerent partners
(Gulati, 1995, 1999; Ring and van de Ven, 1992).
Through these increasing interactions with
their partners, companies are expected to develop
general-purpose partnering capabilities (Lyles,
1988; Oster, 1999). Knowledge of how to manage
inter-ﬁrm partnerships will help them establish
new partnerships with other companies (Dyer
and Singh, 1998; Powell, Koput and Smith-
Doerr, 1996; Ring and van de Ven, 1992) and
improve the likelihood of success of these future
relations (Anand and Khanna, 2000; Barkema et
al., 1997; Dyer and Singh, 1998; Gulati, 1995;
Kale and Singh, 1999; Oster, 1999). This cap-
ability to form and manage partnerships is
relevant in all industries but particularly in
high-tech industries. High-tech industries are
characterized by rapid technological change that
has a major eﬀect on the management of
innovation, not only within companies but also
within partnerships (Hagedoorn, 1993; Powell,
1998). The more companies develop partnering
capabilities, the more these are expected to be
useful in quickly responding to promising new
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nerships.
So far most of the literature on partnership
formation has mainly focused on these general
partnering capabilities, expressing the role of
general experience with partnering through the
number of partnerships in which a company is
involved. However, it is important to stress that it
might be even more important for a ﬁrm to
develop speciﬁc partnering capabilities and create
specialized knowledge about whom to partner
with. Echoing the crucial diﬀerentiation between
general capabilities and speciﬁc, strategic cap-
abilities of companies (Teece and Pisano, 1998),
we understand strategic network capabilities as
ﬁrm-speciﬁc partnering capabilities that enable a
company to place itself in a particular position in
a broader network of partnerships with multiple
companies. These strategic network capabilities,
therefore, do not just reﬂect the general partner-
ing capabilities of companies. As indicated by the
social network literature, these strategic network
capabilities are primarily related to the speciﬁc
intelligence of companies regarding their network
settings and their choice for particular partners
(Burt, 1992; Hagedoorn and Duysters, 2002;
Leik, 1992).
We expect that a company with strategic
network capabilities is able to position itself in
such a way that it can draw information and
learn from a variety of partnerships. In terms of
social network theory (Burt, 1992; Freeman,
1977; Leik, 1992) this implies that a company
with well-developed speciﬁc network capabilities
acts as a strategic player that has manoeuvred
itself in a central position in between other
companies. A company with such a central
position in an inter-ﬁrm network is understood
to have information about both the positioning
of other companies in the network and their
information ﬂows, which enables it to use its
central position to successfully choose future
partners (Freeman, 1977; Knoke and Kuklinski,
1982; Wasserman and Faust, 1994). Further-
more, a central network position shapes a
company’s reputation as a skilled and knowl-
edgeable partner that makes it an attractive
partner for other companies in the network
(Brass, Butterﬁeld and Skaggs, 1998; Powell,
Kogut and Smith-Doerr, 1996).
Finding new partnerships is particularly im-
portant in so-called high-tech industries. It is
well-established that networks in R&D-intensive,
high-tech industries are, given the rapid redun-
dancy of ‘old’ contacts and the need to scan a
variety of options, characterized by a high
turnover in partnerships (Hagedoorn, 1993,
Powell, Kogut and Smith-Doerr, 1996). In that
context it is important to not only maintain a
status-quo based central network position but it
is even more valuable to use this strategic
position to continuously search for new partner-
ships, e.g. to have timely access to new technol-
ogies. A company with a central network position
in between other companies is expected to have
developed speciﬁc strategic network capabilities
in order to use these capabilities to select useful
new partnerships (Sarkar, Echambade and Har-
rison, 2001). Hence,
H1: The larger the strategic, centrality-based,
network capabilities of a company, the higher the
likelihood that it will engage in future partnering
activities.
A second important characteristic of speciﬁc
strategic network capabilities, as indicated by
the social network literature, is found in the
eﬃciency with which a company chooses its
partners. We expect that a company gradually
develops skills which enable it to increase its
eﬃciency in terms of avoiding the maintenance of
redundant partnerships that carry little addi-
tional information (Burt, 1992; Granovetter,
1973). Speciﬁc eﬃciency-based strategic network
capabilities indicate the degree to which a
company has learned to optimize its number of
partnerships within a group of other companies,
avoiding redundant partnerships. In a network of
partnerships each company should be well-con-
nected to others without sustaining a dense,
redundant local network (Burt, 1992). Eﬃ-
ciency-based strategic network capabilities reﬂect
the experience that a company needs in order to
learn which partners to select (i.e. determine the
value of additional information or know-how).
These capabilities also indicate the capacity of a
company to act as a strategic player who is able
to create its own eﬃcient network of partner-
ships, entering into new useful partnerships while
maintaining few or no redundant contacts. The
more eﬃcient and non-redundant the networking
capabilities of a company, the more resources we
can expect it to have for searching for new useful
partnerships.
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network strategy as a rational option for
companies is an important subject of debate in
social network theory. The eﬃciency perspective
has been questioned by Coleman’s (1988) closure
argument, which states, amongst other things,
that a dense and ‘theoretically’ redundant net-
work could be beneﬁcial to companies as it would
create previously unknown opportunities for
future partnership formation. Others stress that
speciﬁc network conditions, for instance in terms
of network environments with unstable popula-
tions and continuous entry of new players, have
to be considered. Seemingly ineﬃcient and dense
local networks surrounding companies might be
helpful in network environments with unstable
populations and continuous entry of new players
with unknown capabilities (Hagedoorn and
Duysters, 2002; Walker, Kogut and Shan,
1997). Alternatively, it can argued that the more
a company uses its eﬃciency-based network
capabilities, avoiding unnecessary duplication of
contacts, the more resources and time it has to
search for new, valuable partnerships. Building
and maintaining partnerships does not come
without costs (Gulati, 1995, 1999; Kale and
Singh, 1999) and the more strategically eﬃcient
companies are in maintaining a non-duplicative
network, the more they can use these freed
resources to enter into new partnerships. Hence,
H2: The larger the strategic, eﬃciency-based, net-
work capabilities of a company, the higher the




We chose the international pharmaceutical bio-
technology industry because of the substantial
partnering activity that characterizes this high-
tech sector during the 1990s (Arora and Gam-
bardella, 1994; Barley, Freeman and Hybels,
1992; Pisano and Wheelwright, 1995; Powell,
1998; Powell, Koput and Smith-Doerr, 1996;
Rothaermel, 2000; Walker, Kogut and Shan,
1997). R&D partnerships are a crucial form of
inter-ﬁrm collaboration in this sector (Hage-
doorn and Roijakkers, 2002; Powell, Kogut and
Smith-Doerr, 1996; Rothaermel, 2000; Walker,
Kogut and Shan, 1997). There are two, related
but also more speciﬁc reasons why this sector is
interesting from the perspective of inter-ﬁrm
strategic networking in the context of R&D
partnerships.
First, besides its important implications for
drug research and development, the development
of pharmaceutical biotechnology has led to the
emergence of an interesting dual market struc-
ture, mainly based on a large number of relatively
small, research-intensive biotechnology ﬁrms and
a small group of very large, established pharma-
ceutical companies (see Powell, 1998). Another
important feature of the modern pharmaceutical
biotechnology industry is the sharply increasing
frequency of inter-ﬁrm R&D partnerships be-
tween these two diﬀerent groups of companies
(see also Powell, 1998; Rothaermel, 2000). While
these developments are by no means unique to
this industry, pharmaceutical biotechnology has
been one of the areas of knowledge, which has
given rise to the largest number of R&D partner-
ships (see, for example, Hagedoorn, 1993). From
a theoretical point of view, it seems particularly
important to understand some speciﬁcs of inter-
ﬁrm R&D collaboration in this sort of high-tech
industry, for example, the networking strategies
and networking capabilities that play a role in the
formation of new R&D partnerships.
Second, in the traditional, organic chemistry-
based pharmaceutical industry of the 1950s and
1960s, inter-ﬁrm R&D collaboration did not play
a very important role. In the post-war era, large
pharmaceutical companies can most accurately
be characterized as highly independent compa-
nies that were mainly following a ‘go-it-alone’
research strategy, involving hardly any formal
R&D partnerships with other companies. While
most of these dominant innovators were intensely
cooperating in research with universities and
other science-based institutions, they were pri-
marily competing with other companies. With the
emergence of biotechnology in the ﬁrst half of the
1970s, however, the pharmaceutical industry
witnessed a rather dramatic change in the nature
of relationships between companies. As a result
of a number of radical scientiﬁc and techno-
logical developments, pharmaceutical companies
were more or less ‘forced’ to adapt their research
strategies to also include a large number of R&D
partnerships. Against this exciting historical
background and complex network setting, it is
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nerships in the context of the speciﬁc networ-
king strategies that companies can follow
in a continued interaction with some of their
partners.
The population of companies used in this
research comprises a total of 230 companies that
are participating in 1325 R&D partnerships
during the period 1991–1998. Using information
from Disclosure, we checked whether partners
are indeed separate companies and not connected
through common governance. We studied ba-
lanced panels, that is, all companies in our
population were in the risk set during the entire
period of observation. This means that they are
assumed to have had the opportunity to form
partnerships during the entire period.
Variables
The dependent variable ‘R&D partnerships’ is a
dichotomously coded variable for the occurrence
of an R&D partnership for each year during the
period 1991–1998. Each dependent variable takes
the value of 1 when a company entered into an
R&D partnership and 0 if this did not occur in a
given year.
The following two core independent variables
(strategic, centrality-based, network capabilities
and strategic, eﬃciency-based, network capabil-
ities) are well-established network indicators
from social network analysis that are crucial for
testing our hypotheses. The ﬁrst of these two
variables measures the degree to which compa-
nies are able to take a central position in an inter-
ﬁrm network through which they can position
themselves strategically in between the other
companies (see H1). The second network variable
measures the degree to which companies are
eﬃcient and selective in choosing their partners,
looking for partnerships with companies that do
not duplicate the linkages that they already have
with other companies (see H2).
The variable ‘strategic, centrality-based, net-
work capabilities’ refers to the relative between-
ness measure of centrality, as suggested by
Freeman (1977). This measure is based on the
idea that companies control information ex-
change between other companies in a network
to the extent that they are positioned on the
geodesic path or shortest path between them.
This measure is calculated using UCINET 5
(Borgatti, Everett and Freeman, 1999). A more
technical explanation of this variable is provided
in Appendix I.
The indicator for ‘strategic, eﬃciency-based,
network capabilities’ is based on Burt’s (1992)
hierarchy measure, which is in fact an adjustment
of a constraint measure. Constraint indicates the
degree of redundancy in the partnerships of a
company in the sense that it measures the extent
to which the company has partners that also
cooperate intensely among themselves. In that
case, the constraint posed by a single partner on a
focal company is likely to be highest if the
partner is part of a completely connected local
network or clique. If the company is also related
to other clique members, the likelihood that the
company will gain access to new knowledge
through its relation with this partner is relatively
low. A high degree of constraint thus indicates
that the partners of a company are densely
connected with each other, while a low degree
of constraint speciﬁes that this local network of a
company is sparsely linked. Hierarchy then
measures the extent to which the aggregate
constraint on a company is concentrated in its
partnership with a single other company. This
measure is also calculated with UCINET 5
(Borgatti, Everett and Freeman, 1999). A more
technical explanation of this variable is found in
Appendix I.
Both network capabilities measures were cal-
culated until the end of the ﬁve-year period
preceding the given year, so the starting year for
measuring these independent variables is 1986.
We use this ﬁve-year moving-window approach
because we assume that only during these few
previous years the partnering capabilities of
companies are likely to aﬀect current partnership
formation (Gulati, 1995). This ﬁve-year moving
window also enables us to control for left
censoring in the data set. In a separate analysis,
we will apply a cumulative approach, which
assumes that all ﬁrm activity that has taken place
until the year before the given year can inﬂuence
partnering behaviour.
Control variables
Given the extensive literature on general partner-
ing capabilities, in terms of the experience of
companies with partnerships, we will apply
indicators of these capabilities only as control
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various measures of their general, experience-
based, partnering capabilities for each year
during the period 1991–1998. These variables
are also based on ﬁve-year moving windows,
similar to the calculations for strategic network
capabilities variables.
The ‘general, experience-based, partnering
capabilities’ of companies are measured as their
total number of R&D partnerships in the
pharmaceutical biotechnology industry. A related
control variable relates to the possible eﬀect
of ‘non-biotechnology general, experience-
based, ‘partnering capabilities’ of companies
on the likelihood of their future R&D partner-
ships. This variable considers the number of
partnerships of ﬁrms in other sectors than
pharmaceutical biotechnology. We include this
control variable because the experience of com-
panies with R&D partnering in other industries
might add to their capabilities in managing inter-
ﬁrm relationships (Lyles, 1988; Ring and van de
Ven, 1992).
The ‘contractual nature’ of R&D partnerships
is a variable that controls for the eﬀect of the
experience of companies with equity-based joint
ventures or contractual partnerships (R&D pacts,
joint development agreements and R&D con-
tracts) on subsequent partnering behaviour (Dyer
and Singh, 1998; Gulati, 1995; Osborn and
Hagedoorn, 1997). It is established that most of
the recently formed R&D partnerships in phar-
maceutical biotechnology are of a contractual
nature, while there are only few equity-based
joint ventures (Roijakkers and Hagedoorn,
2003). The degree to which companies have
experience in forming contractual partnerships
might aﬀect their future partnership formation
that, in all likelihood, is characterized by
contractual agreements. This variable measures
the share of contractual agreements in the total
number of pharmaceutical biotechnology R&D
partnerships of companies.
We also control for the ‘regional nature’ of
partnerships of ﬁrms as the share of all regional
partnerships in their total number of pharma-
ceutical biotechnology R&D partnerships. Re-
gional partnerships are registered according to
their region of origin (North America, Europe,
Asia, other regions) in which the headquarters of
partners are located. The degree to which
companies use international partnerships is one
of the most widely used control variables in this
line of research. It refers to the role played by
international partnerships which seems quite
diﬀerent from the role played by partnerships
within trading blocks (Buckley and Casson, 1988;
Dyer and Singh, 1998). Firms do not usually
possess the same amount of information on
potential ‘foreign’ partners as they would on
possible partners within the same region and the
costs for obtaining information on international
partners are much higher.
Several researchers have shown that the size of
companies inﬂuences the extent to which they
form R&D partnerships (Mytelka, 1991; Powell
and Brantley, 1992). This population includes a
large number of small ﬁrms. Unfortunately, we
could not obtain yearly information on the size,
i.e. revenues or numbers of employees, of most of
these, often privately held, small companies. One
solution would be to focus our study on a subset
of only the largest pharmaceutical and chemical
ﬁrms for which these kinds of yearly data are
more readily available. In that case our ﬁndings
would not be representative for the pharmaceu-
tical biotechnology sector at large. However, the
literature indicates that in R&D-intensive indus-
tries the number of patents of companies does to
a large extent also express their size (Acs and
Audretsch, 1989; Griliches, 1998). For this study,
we found a correlation of 0.92 between the
number of patents and revenues for about 40%
of the companies in our population, for which we
were able to ﬁnd data on their size. We use the
total number of US patent applications of each
company. Logarithms are taken to correct for the
large number of patent applications of large
companies.
In our models, we control for the time since the
last R&D partnership was established. We
assume that the more years have passed since
ﬁrms have formed their last partnership, the less
likely they will engage in new R&D partnerships
(Gulati, 1999). The variable ‘duration’ was
constructed to record the time elapsed since the
prior partnership of ﬁrms. This variable is set to 0
at the outset.
The presence of a particular trend in new R&D
partnership formation over time could seriously
bias our results. Therefore, to control for possible
eﬀects of time, we have included year dummies,
‘time eﬀect (1991–1998)’, in our models using the
year 1997 as a reference.
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Data for the dependent variable, for the indica-
tors of strategic network capabilities, and for
some of the control variables were obtained from
the MERIT-CATI database, a comprehensive
data set that comprises information on R&D
partnerships (Hagedoorn, 1993; Mowery, Oxley
and Silverman, 1998). This databank contains
information on thousands of technology-related
inter-ﬁrm partnerships in various sectors. Within
the databank there is information on each
partnership and some information on companies
participating in these partnerships. Partnerships
are deﬁned as mutual interests between indepen-
dent companies that are not linked through
majority ownership. In the CATI database, only
those partnerships are being recorded that
involve either mutual technology transfer or
some form of jointly undertaken R&D. Informa-
tion is also collected on joint ventures with R&D
activities.
The data on patents, which we use as a
measure of size, are taken from the US Patent
and Trademark Oﬃce database. Although this
US data could imply a bias in favour of US
companies and against non-US ﬁrms, the patent
literature suggests several reasons to choose US
patent data (Patel and Pavitt, 1991). Frequently
mentioned are the importance of the US market,
the genuine patent protection oﬀered by US
authorities, and the level of technological sophis-
tication of the US market which makes it almost
compulsory for non-US companies to ﬁle patents
in the USA. These reasons are particularly
relevant for the pharmaceutical biotechnology
industry (Powell, 1998).
In addition, in order to classify companies into
a number of groups, used in the statistical
analysis, we collected information on the activ-
ities, products, and services provided by each ﬁrm
in our population. We used various sources of
information such as the Institute for Biotechnol-
ogy Information, the US Securities and Exchange
Commission, World Scope Global Researcher,
Amadeus and Dun & Bradstreet’s Linkages.
Statistical method
We apply panel data analysis for our empirical
testing (Baltagi, 1995; Heckman, 1981; Hsiao,
1986; Klevmarken, 1989; Wansbeek, 2001), to
address concerns of unobserved heterogeneity,
we employ group-based ﬁxed eﬀects logit models
for panel data (see Ahn, Lee and Schmidt, 2001;
Brainard, 1997; Greene, 2000). Group-based
ﬁxed eﬀects models treat the unobserved group
eﬀect as a constant over time. This entails
computing a separate constant term for each
group of companies and including a dummy
variable for each. We use 12 dummy variables to
control for possible eﬀects of these diﬀerent
groups of companies where preferences for
R&D partnership formation may vary across
groups. Based on well-established research by,
amongst others, Arora and Gambardella (1994),
Barley, Freeman and Hybels (1992), McMillan
and Narin (2000), Pisano (1994), Powell (1998),
Powell and Brantley (1992), Rothaermel (2000)
and Senker (1998), we classify companies that are
operating in the pharmaceutical biotechnology
industry into a number of homogeneous groups.
2
These groups are expected to exhibit clear
diﬀerences in their R&D partnering behaviour.
We coded companies with 1 if they belong to a
speciﬁc group of companies and with 0 if they are
not part of this group.
In the following equation, we propose such a
group-based ﬁxed eﬀects logit model in which a
variable’s positive coeﬃcient indicates that it
promotes the occurrence of an event, i.e. the
formation of a new R&D partnership:





In equation 1, P(yit 5 1) is the probability that y
takes the value 1 at time t for company i. This
probability is a function of a time-varying vector
2These groups are: (1) Product-producing biotechnology
ﬁrms that focus on therapeutics; (2) product-producing
biotechnology ﬁrms that focus on vaccines; (3) product-
producing biotechnology ﬁrms that focus on diagnos-
tics; (4) service-providing biotechnology ﬁrms that focus
on screening; (5) service-providing biotechnology ﬁrms
that focus on IT solutions; (6) biotechnology ﬁrms that
combine two or more of these activities; (7) pharmaceu-
tical companies that focus on therapeutics; (8) pharma-
ceutical companies that have combined activities in
therapeutics, vaccines, diagnostics; (9) diversiﬁed phar-
maceutical companies that focus on therapeutics; (10)
diversiﬁed pharmaceutical companies that have com-
bined activities in therapeutics, vaccines, diagnostics;
(11) diversiﬁed chemical companies that focus on
therapeutics; (12) diversiﬁed chemical companies that
have combined activities in therapeutics, vaccines,
diagnostics.




terizes company i, and a vector of unknown
parameter b:aj is a separate time-invariant
intercept (dummy variable), computed for each
group j.
Results
Table 1 provides descriptive statistics for the
population and a correlation matrix. Table 2
displays the estimation results of two group-
based ﬁxed eﬀects panel logit models using
LIMDEP 8.0. Given the high degree of correla-
tion between the variables indicating the strate-
gic, centrality-based, network capabilities of
companies and their general, experience-based,
partnering capabilities (see Table 1), the eﬀects of
these variables will be reported separately. We
only report the results of the moving window
approach because the results of the cumulative
approach turned out to be not signiﬁcantly
diﬀerent.
We stated that the strategic, centrality-based,
network capabilities of companies are expected to
have a positive impact on the likelihood of their
future partnering activities (H1). The estimates of
the indicator for speciﬁc centrality-based cap-
abilities are positive and signiﬁcantly diﬀerent
from zero in both models (see Table 2). Hypoth-
esis 2 argues that the larger the strategic,
eﬃciency-based network capabilities of compa-
nies, the higher the likelihood that they will form
new R&D partnerships. Both models in Table 2
show that the estimates of the indicator for these
strategic network capabilities of companies have
a signiﬁcant, positive eﬀect on the likelihood of
their future partnering. These results clearly
indicate that the strategic network capabilities
of companies, expressed through their network
centrality and their eﬃciency in choosing part-
ners, have the expected predicting power regard-
ing the likelihood of future partnership formation
by these companies.
The more general, experience-based partnering
capabilities of companies, developed either within
the pharmaceutical biotechnology industry or in
other sectors of industry, do not appear to play a
very important role (see also Table 2). In
separate, unreported analysis, we included a
squared term for these variables to detect a
possible inverted U-shaped relationship between
the number of previous partnerships and the
likelihood of future partnerships. Some contribu-
tions (Chung, Singh and Lee, 2000; Gulati, 1995;
Saxton, 1997) point at such a curve linear
relationship between the degree to which compa-
nies have established partnerships in the past and
their future partnership formation. However, our
analysis did not indicate such an inverted U-
shaped relationship.
The signiﬁcant eﬀects of some of the other
control variables, that is, size, duration and most
of the year dummies appear to persist across both
models in Table 2. The organizational form of
R&D partnerships, the distribution of partner-
ships over diﬀerent international regions and the
speciﬁc group to which a company belongs,
however, do not seem to aﬀect the likelihood of
partnership formation. The latter result indicates
the importance of strategic network capabilities
of companies for future partnership formation,
regardless of the particular group to which
companies belong.
Discussion
Our results suggest that strategic, centrality-
based, network capabilities and strategic eﬃ-
ciency in choosing partners are more relevant for
companies to enter into new partnerships than
their general experience-based partnering cap-
abilities. Learning opportunities for partnering
companies become clear in their ability to
strategically place themselves in a central net-
work position in between other companies, which
gives them access to multiple sources of informa-
tion from the network. This clearly resonates
some crucial understanding from social network
theory (Burt, 1992; Freeman, 1977) that stresses
the strategic importance of controlling ﬂows of
information through access to a variety of useful
contacts. In addition, companies that engage in
inter-ﬁrm partnering seem to learn how to create
their own eﬃcient network of partnerships and
then select new partners who can further con-
tribute to the body of knowledge already present
in their local network. The importance of such
eﬃciency-based network capabilities is clearly
related to the strategy advocated in social net-
work analysis that stresses the crucial role of
strategic behaviour based on avoiding redundant
in networks contacts (Burt, 1992). These strategic

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Inter-Firm R&D Networks 47network capabilities have to be of an up-to-date
nature, as we found that older contacts loose
their value because they have a negative eﬀect on
the formation of future partnerships.
From a managerial perspective, this implies
that building up elaborate experience through a
large number of partnerships as such, linking up
to any company that is available, is not that
helpful if a company intends to be successful in
ﬁnding new partners. It is much more relevant to
use speciﬁc networking capabilities which enable
a company to place itself in a well-connected
position among partners that are also well-placed
in their networks. Therefore, it is important that
companies maintain a status-quo based central
network position or move to a more central
position in the network to continuously search
for and select useful new partnerships. In that
context, companies have to be eﬃcient and avoid
wasting too much eﬀort on cooperating with as
many partners as possible. This would create a
lot of experience, but the scanning of many
potential partners and the creation and main-
tenance of a large number of partnerships is a
time-consuming and expensive activity that takes
up a lot of managerial resources that could be
used for alternative purposes. Instead, companies
are advised to be eﬃcient in their networking
strategy and to avoid experimenting with a large
number of partnerships with companies that are
not well connected in the overall network. This
also implies that companies have to renew their
partnerships on a regular basis and avoid their
portfolio of partnerships becoming outdated with
historical partnerships that might have become
redundant. To remain an attractive partner to
others, a company has to renew its contacts on a
regular basis to ensure that it is still ‘in the loop’
and that its portfolio of partnerships is attractive
to other active networking companies as well.
We submit that some additional understanding
of this important role for strategic network
capabilities can be found in the context of
understanding the speciﬁcs of R&D partnering
Table2. Group-based ﬁxed eﬀects panel logit estimates, N51840
Variable 12
Strategic, centrality-based, network capabilities 0.09132** (0.02542) 0.11252** (0.01784)
Strategic, eﬃciency-based, network capabilities 0.93580** (0.17007) 0.93113** (0.17006)
General, experience-based, partnering capabilities 0.03997 (0.03524)
Non-biotechnology general, experience-based, partnering capabilities 0.00375 (0.00845) 0.00472 (0.00841)
Contractual nature 0.01379 (0.18730) 0.04663 (0.18490)
Regional nature  0.13118 (0.17235)  0.10489 (0.17085)
Size 0.34786** (0.08533) 0.35585** (0.08482)
Product-producing biotech ﬁrms (therapeutics)  0.16621 (0.19632)  0.12032 (0.19204)
Product-producing biotech ﬁrms (vaccines)  0.45072 (0.63817)  0.39636 (0.63642)
Product-producing biotech ﬁrms (diagnostics)  0.17570 (0.82080)  0.14345 (0.82128)
Service-providing biotech ﬁrms (screening)  0.08132 (0.31697)  0.03089 (0.31399)
Service-providing biotech ﬁrms (IT solutions)  0.06865 (0.34809)  0.00616 (0.34366)
Biotech ﬁrms with combined activities 0.05550 (0.23655) 0.11068 (0.23156)
Pharmaceutical ﬁrms (therapeutics) 0.19481 (0.27902) 0.27785 (0.26904)
Pharmaceutical ﬁrms with combined activities 0.21957 (0.37069) 0.29074 (0.36483)
Diversiﬁed pharmaceutical ﬁrms (therapeutics)  0.34892 (0.30830)  0.29990 (0.30503)
Diversiﬁed pharmaceutical ﬁrms with combined activities 0.02804 (0.42894) 0.11407 (0.42036)
Diversiﬁed chemical ﬁrms (therapeutics)  0.52937 (0.33275)  0.47276 (0.32838)
Diversiﬁed chemical ﬁrms with combined activities  0.07981 (0.54991)  0.02499 (0.54705)
Duration  0.27704** (0.06121)  0.28275** (0.06112)
Time eﬀect (1991)  3.46744** (0.37234)  3.49931** (0.37006)
Time eﬀect (1992)  1.70431** (0.24659)  1.75943** (0.24191)
Time eﬀect (1993)  1.16765** (0.23100)  1.23660** (0.22336)
Time eﬀect (1994)  0.55381** (0.21593)  0.61070** (0.21028)
Time eﬀect (1995)  0.28403 (0.20803)  0.33075* (0.20398)
Time eﬀect (1996)  0.20725 (0.20048)  0.23167 (0.19907)
Time eﬀect (1998)  0.72721** (0.20303)  0.68705** (0.19900)
Log-likelihood  1006.67  1007.33
Notes: Standard errors in parentheses; signiﬁcance-levels *po0.10; **po0.01; N5number of observations.
48 J. Hagedoorn, N. Roijakkers and H. Van Kranenburgin high-tech sectors such as the pharmaceutical
biotechnology industry. High-tech industries are
characterized by their ever-shortening technology
development cycles and short product life cycles,
which form a constant pressure on companies to
respond quickly to changing market needs and to
new technological opportunities. As mentioned
before, timely access to new technologies and
state-of-the-art scientiﬁc knowledge that is devel-
oped outside the boundaries of the ﬁrm is crucial
to competitive success in these industries. As a
result of a number of factors – globalization of
markets, the increasing complexity of technolo-
gies and the increasing costs of R&D – even the
largest ﬁrms are no longer able to individually
monitor all the technological and scientiﬁc
developments that are important for their core
markets (Hagedoorn, 1993). Cooperation with a
variety of partners enables companies to simul-
taneously detect several scientiﬁc and technolo-
gical developments, as well as respond quickly to
the most promising new opportunities. As
companies undertake joint R&D with several
other companies, they learn how to position
themselves for access to numerous sources of
information and how to optimally select partners
in terms of their knowledge contribution. These
strategic network capabilities not only make
companies attractive partners for other ﬁrms,
because they are well connected, but they also
allow them to choose from a wide range of
possible partners (Oster, 1999; Rothaermel and
Deeds, 2001). Based on their speciﬁc strategic
network capabilities, companies are thus able to
create a portfolio of partnerships that allows
them to tap into many diﬀerent sources of
promising research.
Companies operating in an innovative high-
tech industry face a high degree of technological
uncertainty, which aﬀects the success of their
innovation strategies, their new product
launches, and the eﬀectiveness of their R&D
capabilities. Obviously, well-developed internal
R&D capabilities are important for a successful
innovation strategy in a high-tech environment.
However, as all leading companies have to
balance an internal innovation strategy with an
external R&D partnering strategy, strong inter-
nal R&D capabilities are also important for the
external attractiveness of companies that intend
to link up to other companies with innovative
potential. External R&D resources, generated
through R&D partnerships, enable a company to
quickly respond to changes in its technological
environment without having to build up full
internal R&D capacity in speciﬁc areas of
research because resources are shared with
R&D partners. Given the uncertainty that
surrounds technological development, a success-
ful R&D partnering strategy, which enables a
company to remain active in building new
partnerships, appears to demand a variety of
up-to-date R&D partnerships with a portfolio of
diverse contacts through companies with inter-
esting R&D resources.
This broad portfolio of partnering options is
clearly available in the pharmaceutical biotech-
nology industry, where the majority of R&D
partnerships are formed between large pharma-
ceutical and chemical companies and small,
R&D-intensive biotechnology ﬁrms (Powell,
1998; Rothaermel, 2000). For instance, in our
population, about 21% of the companies are
large pharmaceutical and chemical companies,
nearly 69% are small biotechnology ﬁrms and the
remainder is relatively small group of medium-
sized, specialized pharmaceutical companies. In
terms of R&D partnerships, about 68% are
large–small coalitions. These large pharmaceuti-
cal and chemical companies typically provide
their many smaller partners with ﬁnancial sup-
port and regulatory know-how, in return for
which large companies acquire access to the
speciﬁc research skills of these small biotechnol-
ogy companies (Arora and Gambardella, 1994;
Barley, Freeman and Hybels, 1992; Pisano, 1994;
Powell, 1998; Shan, Walker and Kogut, 1994).
Large pharmaceutical and chemical companies
can secure their future access to promising new
biotechnologies by building up their stock of
knowledge about how and with whom to partner,
while also developing their absorptive capacity
through internal innovative activities. For small
biotechnology ﬁrms, their visibility as a partner
that possesses state-of-the-art technological
know-how allows them to enter into future
R&D partnerships with a variety of companies.
From a managerial perspective on these
particular inter-ﬁrm pharmaceutical biotechnol-
ogy R&D networks, these large pharmaceutical
companies and diversiﬁed chemical companies
can use a variety of R&D partnerships with
dedicated biotechnology companies as long as
these companies possess the necessary technolo-
Inter-Firm R&D Networks 49gical knowledge and interesting linkages to other
companies. Again, even these large chemicals are
advised to be eﬃcient in their networking strategy
and to avoid costly and time-consuming partner-
ing experiments with an indiscriminate number of
partners that are either not operating at the
technological frontier of biotechnology or that
are not well-connected to other interesting
companies. Also in this particular context, a
successful R&D partnering strategy demands a
variety of up-to-date biotechnology R&D part-
nerships through a portfolio of diverse contacts
with a variety of companies that are able to
develop interesting new biotechnological research
resources. Even more than for large companies,
small dedicated biotechnology ﬁrms have to be
eﬃcient in their networking strategy, for them
costly and time-consuming partnering experi-
ments with a large number of partners can easily
surpass the maximum of managerial resources
available to each of these smaller companies.
Avoiding over-dependence on a few large part-
ners indicates that for this group of companies a
successful R&D partnering strategy also de-
mands a variety of up-to-date R&D partnerships,
with a diverse portfolio of partnerships made
with a variety of companies.
Conclusions
Apparently, in this high-tech industry, it is not
the general experience-based capabilities of com-
panies but much more their speciﬁc strategic
network positioning and the eﬃciency with which
they choose their partnerships that increase the
likelihood that companies will continue to form
partnerships. If companies want to remain
involved with inter-ﬁrm partnerships with other
interesting companies, it is important that they
are selective and eﬃcient in their partner choice
instead of indiscriminately engaging in partner-
ships across-the-board, using every opportunity
for forming partnerships that comes along.
Furthermore, those companies that strategically
place themselves in an overall network of
partnerships beneﬁt from such a central position,
as they are also the ones that will be invited to
participate in future partnering activities.
Our ﬁndings not only have some interesting
empirical and managerial implications for under-
standing the partnering behaviour of companies,
they also have some interesting theoretical
implications. Amongst other things, this implies
that social network theory can be instrumental in
improving our understanding of inter-ﬁrm part-
nerships. Social network literature has moved
away from a general understanding of the
formation of networks towards a more inter-
organizational perspective on the speciﬁc struc-
ture of networks and the strategic behaviour of
network ‘players’. The above demonstrates that
the management literature on inter-ﬁrm networks
could beneﬁt from a further integration of major
elements from social network theory to improve
the understanding of the eﬀectiveness with which
companies create networks of partnerships.
Obviously there are a number of options for
further study. This study only looks at one
industry, pharmaceutical biotechnology. Further
study of other high-tech sectors can reveal
whether these eﬀects are also found in a larger
group of industries. Using a broader set of
strategic network capabilities and a wider range
of forms of partnering can also improve our
understanding the role of these company cap-
abilities. Given this research agenda, our current
contribution has limitations, but it also provides
us with some interesting answers to a number of
relevant questions.
Appendix I Technical details on
network measures
The variable strategic, centrality-based, network
capabilities refers to the relative betweenness
measure of centrality Freeman (1977). Assuming
that two companies i and j are indiﬀerent as to
which geodesic is used, the probability of using
any one is 1
gij where gij is the number of geodesics
linking i and j. If company m lies between
companies i and j on a geodesic, the number of
such geodesics that involve m is gimj (Knoke and
Kuklinski, 1982; Wasserman and Faust, 1994).
Freeman (1977) has shown that the maximum
value of betweenness centrality is achieved by the
central company in a star-shaped network. That
value is N2 3Nþ2
2 for undirected networks. We
assume undirected networks of cooperating
companies as R&D partnerships in our dataset
are characterized by mutual exchanges of tech-
nological knowledge. An appropriate measure of
relative centrality for company m is the following
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p. 53):








N2   3N þ 2
i 6¼ j ð2Þ
This relative centrality is expressed in percen-
tages, where values range between 0% and 100%,
with higher scores indicating greater ﬁrm cen-
trality relative to other network partners. We use
this relative centrality measure because an
absolute measure of betweenness cannot be used
to compare centralities of networks with diﬀerent
number of units. This measure is calculated using
UCINET 5 (Borgatti, Everett and Freeman,
1999).
The indicator for strategic, eﬃciency-based,
network capabilities is based on Burt’s (1992)
hierarchy measure, which is in fact an adjustment
of a constraint measure. Constraint refers to the
focal company’s (i) investment in reaching
partner j multiplied by the lack of structural
holes around j with which i could negotiate a
favourable rate of return on investment. Invest-
ment is the proportion of the focal company’s
network time and energy that leads to partner j
and the lack of holes around j. Their product
deﬁnes j’s constraint on i :
cij ¼ð i’s investment in reaching jÞ






Oj i 6¼ q 6¼ j
ð3Þ
and the aggregate constraint on i is the sum of
constraint from i’s partnerships with each of the
N partners: C ¼
P
j cij. The partner-speciﬁc con-
straint in equation 3 varies from a minimum of 0
up to a maximum of 1. The maximum occurs if j
is the only partner of i. The minimum occurs if j
has no partnerships with companies with whom
you could replace partner j (Burt, 1992, p. 64,
equation 2.7).
First, for each partner j of company i,w e
compute the ratio of partner-speciﬁc constraint
to the average level of constraint per partner,
RCij, which tells us how much one particular
partner j is a more severe source of constraint to
company i than any of its other partners. This





In equation 4, cij measures the constraint posed
on company i by partner j, N is the total number
of partnerships of company i, C is the sum of
constraint across all N partnerships, and C/N is
the average constraint per partner. The constraint
ratio is 1 for partner j posing an average level of
constraint on company i.
As a next step, we apply the so-called Cole-
man-Theil disorder index to generate the actual
hierarchy measure. This method multiplies the
sum of all partner-speciﬁc constraint ratios by its
natural logarithm and divides the outcome by the
maximum sum possible. For company i the














This measure equals 0 when constraint is the
same for each partner of a company. It measures
1 when all constraint is concentrated in a single
partnership. In other words, higher values of
hierarchy indicate that a company is more
eﬃcient in choosing its partners in terms of the
contribution that partners can make to the body
of knowledge that the company can already
access through its other partnerships. Lower
values of hierarchy indicate more redundancy in
partnerships through duplication of information
ﬂows. This measure is also calculated with
UCINET 5 (Borgatti, Everett and Freeman,
1999).
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